Fadi Braiteh

9.2k citations

76 papers · 5.6k indexed · 4 hit papers · h-index 29

Impact in

Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- CAR-T cell therapy research
Cancer Research top 2%
- Cancer Genomics and Diagnostics

Papers in

Oncology 57
- Cancer Immunotherapy and Biomarkers 18
- Colorectal Cancer Treatments and Studies 13
- Pancreatic and Hepatic Oncology Research 10
- Cancer Treatment and Pharmacology 8
- Lung Cancer Research Studies 8
- HER2/EGFR in Cancer Research 7
Hepatology 7

Co-authors: Alexander I. Spira Achim Rittmeyer Julien Mazières C. Lewanski Marcin Kowanetz Johan Vansteenkiste Á. Artal David C. Smith
Journals: Annals of Oncology (16 papers)Journal of Clinical Oncology (7 papers)Clinical Cancer Research (6 papers)Journal of Thoracic Oncology (4 papers)JAMA Oncology (3 papers)
Partner nations: United States Spain United Kingdom

In The Last Decade

Fadi Braiteh

74 papers receiving 5.6k citations

Hit Papers

align trajectories log scale

Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer 2019 · 441 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2019 Annals of Oncology
2018 JAMA Oncology
2017 Journal of Clinical Oncology
2016 The Lancet

Peers

Countries citing papers authored by Fadi Braiteh

Since Specialization

Citations

This map shows the geographic impact of Fadi Braiteh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fadi Braiteh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fadi Braiteh more than expected).

Fields of papers citing papers by Fadi Braiteh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fadi Braiteh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fadi Braiteh. The network helps show where Fadi Braiteh may publish in the future.

Co-authors

The 25 scholars most cited alongside Fadi Braiteh, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Fadi Braiteh Line = papers co-authored together Fadi Braiteh links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma ESMO Open ·Byoung Chul Cho, Konstantin Penkov, Igor Bondarenko, Sesen, Joanna Pikiel, Hee Kyung Ahn, Marta Costa‐Romero, M. A. Osipov, Traci Hodson, Fadi Braiteh, Antoni Ribas, Juneko E. Grilley‐Olson, Iwona Ługowska, Vinícius Bonato, Edna M. Stewart, 마경화, G. Timothy Petito, Deborah B. Bowles, XU Zhi-ying, Melissa L. Johnson	2023	4
2	Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study Clinical Cancer Research ·Daniel P. Petrylak, Yohann Loriot, David R. Shaffer, Fadi Braiteh, John D. Powderly, Lauren C. Harshman, Paul Conkling, Jean‐Pierre Delord, Michael S. Gordon, Joseph W. Kim, Indrani Sarkar, Kobe Yuen, Edward E. Kadel, Sanjeev Mariathasan, Carol O’Hear, Sujata Narayanan, Marcella Fassò, Susheela Carroll, Thomas Powles	2021	54
3	P-95 EV-202: An open-label, multicenter, phase 2 study of enfortumab vedotin in patients with previously treated locally advanced or metastatic solid tumors, including upper gastrointestinal cancers Annals of Oncology ·Kei Muro, Justine Y. Bruce, Joaquina Baranda, Seema Rao Gorla, Chunzhang Wu, Fadi Braiteh	2021	0
4	Association of Tumor Mutational Burden and Immune Gene Expression with Response to PD-1 Blockade by Sasanlimab Across Tumor Types and Routes of Administration Targeted Oncology ·Siwen Hu‐Lieskovan, Fadi Braiteh, Juneko E. Grilley‐Olson, Xiao Wang, Alison Forgie, Vinícius Bonato, Ira Jacobs, Jeffrey Chou, Melissa L. Johnson	2021	2
5	A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue Sarcoma Clinical Cancer Research ·Sant P. Chawla, Sanjay Goel, Warren Chow, Fadi Braiteh, Arun S. Singh, Juneko E. Grilley‐Olson, Atsushi Osada, Iulian Bobe, Richard F. Riedel	2020	29
6	EP1.12-06 New Treatment Option for ES-SCLC: Patient Characteristics and Use of an Atezolizumab Regimen in the Real-World Setting Journal of Thoracic Oncology ·Steve McCune, Claudia Lilibeth Vélez Hidalgo, T.P. Wiseman, 聡坂田, Leora Horn, Ivor Percent, Tarek Mekhail, Jerome H. Goldschmidt, Ticiana Leal, Gary R. MacVicar, Fadi Braiteh, Davey B. Daniel, Maen Hussein, Aaron S. Mansfield, Sivuonthanh Lam, Ann Johnson, S. Morris, Alexander I. Spira	2019	1
7	Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus Clinical Cancer Research ·Alexa B. Schrock, Dean C. Pavlick, Samuel J. Klempner, Jon Chung, Pr. Romdhane Khemakhem, Allison W. Welsh, Lauren Young, B Leyland-Jones, Rodolfo Bordoni, Richard D. Carvajal, Joseph Chao, Razelle Kurzrock, Jason K. Sicklick, Jeffrey S. Ross, Philip J. Stephens, Craig Devoe, Fadi Braiteh, Siraj M. Ali, Vincent A. Miller	2018	54
8	Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial Annals of Oncology ·A. Dimitrios Colevas, Rastislav Bahleda, Fadi Braiteh, Ani Sarkis Balmanoukian, Irene Braña, Nicole G. Chau, Indrani Sarkar, Luciana Molinero, William Grossman, Fairooz F. Kabbinavar, Marcella Fassò, Carol O’Hear, John D. Powderly	2018	107
9	HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma Journal of Clinical Oncology ·Sunil R. Hingorani, Lei Zheng, Andrea J. Bullock, Tara Elisabeth Seery, William Proctor Harris, Darren Sigal, Fadi Braiteh, Paul S. Ritch, Mark M. Zalupski, Nathan Bahary, Paul E. Oberstein, Andrea Wang‐Gillam, Wilson Wu, Dimitrios Chondros, Ping Jiang, Sihem Khelifa, Jie Pu, Carrie Aldrich, Andrew Hendifar Hit paper breakdown →	2017	365
10	PEGPH20 improves pfs in patients with metastatic pancreatic ductal adenocarcinoma: A randomized phase 2 study in combination with nab-paclitaxel/gemcitabine Annals of Oncology ·Sunil R. Hingorani, Andrea J. Bullock, Tara Elisabeth Seery, Lei Zheng, Darren Sigal, Paul S. Ritch, Fadi Braiteh, Mark M. Zalupski, Nathan Bahary, William Proctor Harris, Jie Pu, Carrie Aldrich, Sihem Khelifa, Wilson Wu, Joaquina Baranda, Ping Jiang, Andrew Hendifar	2017	5
11	Tumor Hyaluronan May Predict Benefit From PEGPH20 When Added to nab Paclitaxel/Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (mPDA) Annals of Oncology ·Andrew Hendifar, Andrea J. Bullock, Tara Elisabeth Seery, Lei Zheng, Darren Sigal, Paul S. Ritch, Fadi Braiteh, Mark M. Zalupski, Nathan Bahary, William Proctor Harris, Jie Pu, Fangru Lian, Junming Zhu, Wilson Wu, Joaquina Baranda, Ping Jiang, Sunil R. Hingorani	2017	0
12	Lack of pharmacokinetic drug–drug interaction between ramucirumab and irinotecan in patients with advanced solid tumors Cancer Chemotherapy and Pharmacology ·Ding Wang, Fadi Braiteh, James J. Lee, Crystal S. Denlinger, Dale R. Shepard, Archana Chaudhary, Yong Lin, Ling Gao, Nicolas-Memmie Mogue, Federico Nasroulah, Patricia LoRusso	2016	2
13	Safety, clinical activity and biomarkers of atezolizumab (atezo) in advanced ovarian cancer (OC) Annals of Oncology ·J. R. Infante, Fadi Braiteh, Leisha A. Emens, Ani Sarkis Balmanoukian, Ana Oaknin, Vahe K. Karachorlu, Nazrul Syafiq Bin Norman, Luciana Molinero, Marcella Fassò, Carol O’Hear, Michael S. Gordon	2016	36
14	Final results of NAPOLI-1: A phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy Annals of Oncology ·Barbara Mor, Andrea Wang‐Gillam, Sabrina Mouzaia, G. Bodoky, Andrew Dean, Yan‐Shen Shan, Gayle Jameson, Teresa Macarulla, Ki Hoon Lee, David Cunningham, J.F. Blanc, Richard Hubner, James F Ochieng, Gilberto Schwartsmann, Fadi Braiteh, Bruce Belanger, Voy Wiederhold, Hangbin Li, Daniel D. Von Hoff, Jens T. Siveke	2016	5
15	Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors Oncology ·Emiliano Calvo, Fadi Braiteh, Daniel D. Von Hoff, Robert R. McWilliams, Carlos Becerra, Matthew D. Galsky, Gayle Jameson, Ji Lin, Scott McKane, Enaksha Wickremsinhe, Scott M. Hynes, Aimee Bence Lin, Karla Hurt, Donald Richards	2016	33
16	A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer Clinical Cancer Research ·Alex A. Adjei, Donald Richards, Anthony B. El-Khoueiry, Fadi Braiteh, Vanesia Amelia Sebayang, Joe Stephenson, Aram F. Hezel, Morris Sherman, Lawrence Garbo, 刘曦子, Cory Iverson, Jeffrey N. Miner, Zancong Shen, Li‐Tain Yeh, Mingxia Gui, David M. Wilson, Kimberly J. Manhard, Prabhu Rajagopalan, Heiko Krissel, Neil J. Clendeninn	2015	16
17	Efficacy and Safety Results From a Phase 2, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy in Advanced Squamous-Cell Non-Small Cell Lung Cancer (sq NSCLC) International Journal of Radiation OncologyBiologyPhysics ·Fred R. Hirsch, Ramaswamy Govindan, Zanete Zvirbule, Fadi Braiteh, Achim Rittmeyer, Cristóbal Belda-Iniesta, Dolores Isla, Thomas M. Cosgriff, Michelle Boyer, Mikio Ueda, Sem H. Phan, David R. Gandara	2014	2
18	Proactive strategies for regorafenib in metastatic colorectal cancer: implications for optimal patient management Cancer Management and Research ·Gazala Khan, Fadi Braiteh, Fancioli Koro Koro, Rebecca A. Moss	2014	17
19	Predictors of Access to Palliative Care Services among Patients Who Died at a Comprehensive Cancer Center Journal of Palliative Medicine ·Nada Fadul, Ahmed Elsayem, J. Lynn Palmer, Tao Zhang, Fadi Braiteh, Éduardo Bruera	2007	90
20	Cryptogenic invasive Klebsiella pneumoniae liver abscess syndrome International Journal of Infectious Diseases ·Fadi Braiteh, Marjorie Golden	2006	53

About Fadi Braiteh

Fadi Braiteh is a scholar working on Oncology, Hepatology, Cancer Research, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine, having authored 76 papers that have together received 5.6k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (18 papers), Lung Cancer Treatments and Mutations (13 papers), Colorectal Cancer Treatments and Studies (13 papers), Pancreatic and Hepatic Oncology Research (10 papers), Cancer Genomics and Diagnostics (9 papers), Cancer Treatment and Pharmacology (8 papers), Lung Cancer Research Studies (8 papers) and HER2/EGFR in Cancer Research (7 papers). The work is most often cited by research in Oncology (4.2k citations), Cancer Research (940 citations), Pulmonary and Respiratory Medicine (2.0k citations), Immunology (1.1k citations) and Pathology and Forensic Medicine (565 citations). Fadi Braiteh has collaborated with scholars based in United States, Spain and United Kingdom. Frequent co-authors include Alexander I. Spira, Achim Rittmeyer, Julien Mazières, C. Lewanski, Marcin Kowanetz, Johan Vansteenkiste, Á. Artal, David C. Smith, Louis Fehrenbacher and Pei He. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, Clinical Cancer Research, Journal of Thoracic Oncology and JAMA Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact